Endoscopic Ultrasound Plus Submucosal Injection for Early Esophageal Cancer

Esophageal Cancer Clinical Trial

Official title:

Efficacy Study of Endoscopic Ultrasound Combining With Submucosal Saline Injection for Pretreatment Staging of T1a and T1b in Patients With Early Esophageal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01555801
• Other study ID #: 112273
• Secondary ID: 1122
• Status: Recruiting
• Phase: N/A
• First received: February 29, 2012
• Last updated: January 23, 2017
• Start date: February 2012
• Est. completion date: December 2018

Study information

• Verified date: January 2017
• Source: Sun Yat-sen University
• Contact: Jian-jun Li, M.D. Ph.D.
• Phone: 86-2087343381
• Email: lijj[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Preoperative accurately staging T1a or T1b in early esophageal cancer is vital for the choices of treatment. At present, the main diagnostic method for early esophageal cancer is endoscopic ultrasound (EUS). However, the accuracy of EUS alone is poor. Thus, it is necessary to improve endoscopic ultrasound examination methods. This project is concerning on the efficacy of EUS combining with submucosal injection of saline for staging T1a and T1b-esophageal cancer. Patients and methods: 80 cases of pathological confirmed early esophageal cancer were randomly divided into two groups: endoscopic ultrasonography group (EUS group) and EUS combining with submucosal injecting saline group (EUS+SIS group). All the cases will be performance by endoscopic or surgical resection; postoperative pathologic diagnosis will be obtained involving echo, depth, margin and other features. The EUS results of two groups of patients will be compared with pathologic results. From comparison, the efficacy and accuracy of EUS+SIS for staging T1a and T1b in esophageal cancer patients will be validated. Through this study, the investigators may develop a routine diagnostic and accurately staging method for early esophageal cancer patients.

Description:

Someone whom may concern our IPD are available to the PI, Jian-jun Li M.D. or at lijj@sysucc.org.cn

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age 18-65 years old, no gender limited;

• Patients with esophageal squamous cell carcinoma who be confirmed by ordinary endoscopy and pathologic biopsy;

• Patients who agree to accept endoscopic resection or surgical excision of the lesion in esophagus;

• patients with normal cardio-pulmonary function and normal coagulative function,are predicted to be tolerated anesthesia and surgery;

• patients who understand test purpose, volunteer to join these study and sign the consent inform.

Exclusion Criteria:

• Patients with stages of T2, T3, or T4 displayed by EUS;

• Patients who can't tolerate endoscopy and surgical treatment for various reasons;

• Patients who have distant metastasis, or multiple source of malignant tumors;

• Patients with blood coagulative disorder;

• Patients don't accept the endoscopic examination or surgical treatment;

• Patients with poor compliancy.

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Device:
• submucosal injection needle ; EUS
The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
• ordinary endosonography(EUS)
These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.

Locations

Country	Name	City	State
China	cancer center, Sun Yat-sen University	Guangzhou city	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity	The stages judged from submucosal injection plus EUS or ordinary EUS will be compared with the pathological results after endoscopic or surgical resection.So the sensitivity,specificity,positive predictive value,negative predictive value and diagnostic accuracy of either submucosal injection plus EUS or ordinary EUS for early esophageal cancer will be measured respectivly.	Participants will be followed for the duration of hospital stay in order to accept endosopic or surgical resection , an expected average of 10 days
Primary	Specificity	As well as sensitivity described above.	Participants will be followed for the duration of hospital stay in order to accept endosopic or surgical resection , an expected average of 10 days
Primary	Diagnostic accuracy	As well as sensitivity described above.	Participants will be followed for the duration of hospital stay in order to accept endosopic or surgical resection , an expected average of 10 days